nnc 112 has been researched along with odapipam in 1 studies
| Studies (nnc 112) | Trials (nnc 112) | Recent Studies (post-2010) (nnc 112) | Studies (odapipam) | Trials (odapipam) | Recent Studies (post-2010) (odapipam) |
|---|---|---|---|---|---|
| 32 | 3 | 7 | 19 | 4 | 3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andersen, PH; Braestrup, C; Grønvald, FC; Guddal, E; Hansen, LB; Hohlweg, R; Nielsen, EB | 1 |
1 other study(ies) available for nnc 112 and odapipam
| Article | Year |
|---|---|
NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists.
Topics: Animals; Benzazepines; Benzofurans; Dopamine; Dopamine D2 Receptor Antagonists; In Vitro Techniques; Male; Rats; Rats, Inbred Strains; Receptors, Dopamine D1; Serotonin | 1992 |